Sep. 9 at 7:24 PM
$NVCR
Ashley’s message (same thing she said last week)
1) GBM stable, growing mid-single digits
2) NVCR top line growth will come from pancreatic and mets
3) Profitability on the way
4) Don’t expect much from lung
My 2 cents: Ashley lacks ‘executive presence’. She looks and talks like a librarian (credit @Tdorsey1776). Russell Crow in Gladiator, she is not.
Ashley can drive #3 by dramatically cutting the
$200M / yr NVCR spends on R&D. vast majority of this spend is clinical trials. By early 2026, the incredibly expensive Trident (n=950) will be over, Panova4 will be over, and only 2 big sized trials will remain (Keynote D58 and Lunar2). D58 is being slow-walked to avoid cannibalization, expect that to continue. Lunar2, I have no idea, but note that NVCR previously said they plan for ~130 clinical sites and currently have < 80.
Thank you for your attention to this matter.
